Skip to content
Inciteful Med
Resources About us Ask a Question

What Are the Best POTS Treatments for hEDS Patients?

Published: | Updated:

Treating POTS in hEDS patients requires a step-wise, highly individualized approach. It starts with lifestyle modifications like abdominal binders, increased salt, and modified recumbent exercise, progressing to targeted medications like fludrocortisone or ivabradine if symptoms persist.

Key Takeaways

  • • Initial POTS treatment focuses on expanding blood volume through high salt intake, hydration, and compression garments like abdominal binders.
  • • Graded recumbent exercise programs can improve autonomic balance but must be modified to protect hypermobile joints.
  • • If lifestyle changes are not enough, doctors prescribe targeted medications based on your specific heart rate and blood pressure patterns.
  • • Co-occurring conditions like MCAS may require doctors to order custom-compounded medications without triggering dyes or fillers.
  • • Gastrointestinal dysmotility may require switching from large salt pills to continuous oral rehydration solutions to manage fluid intake.

Managing Postural Orthostatic Tachycardia Syndrome (POTS) when you have hypermobile Ehlers-Danlos Syndrome (hEDS) follows a step-wise approach. Treatment almost always begins with foundational lifestyle modifications—such as increased salt, high fluid intake, and compression garments—to boost blood volume and prevent blood from pooling [1][2][3]. If symptoms persist despite these changes, doctors will introduce targeted medications tailored to your specific heart rate and blood pressure patterns [4][5][6]. Because hEDS frequently overlaps with other conditions like Mast Cell Activation Syndrome (MCAS) and gastrointestinal issues, your treatment plan will be highly individualized to navigate these complexities [1][7].

Step 1: Foundational Lifestyle Modifications

Before starting prescription medications, doctors recommend non-pharmacological therapies. For many patients, these changes can significantly reduce the burden of dizziness, fatigue, and rapid heart rate [8][9].

  • High Salt and Fluid Intake: The primary goal of consuming extra sodium and fluids is to expand plasma volume (the liquid part of your blood) [10][11]. Because POTS often involves hypovolemia (low blood volume), increasing your intake helps your body pump blood to your brain more efficiently, reducing the severe spike in heart rate when you stand up [10][12]. While general POTS guidelines often recommend consuming several extra grams of salt and liters of water daily, there are no universal hEDS-specific targets; your doctor will provide a specific goal based on your tolerance [4][13].
  • Compression Garments: Wearing tight, medical-grade garments helps physically squeeze blood upward, preventing it from pooling in your lower body. Interestingly, research shows that abdominal binders (compression around the stomach) are particularly effective, and sometimes more user-friendly and successful than waist-high leg stockings [14][15]. This is incredibly useful for hEDS patients, as pulling on tight leg compression can sometimes cause hypermobile finger or wrist joints to subluxate.
  • Graded Exercise Rehabilitation: Exercise programs designed for POTS, such as the Levine protocol or the CHOP modified protocol, are cornerstones of treatment [16][17]. These programs start with recumbent (lying down or seated) aerobic exercises—like rowing or swimming—to prevent POTS symptoms from flaring up, gradually improving your body’s autonomic balance over time [9][8]. For hEDS patients, it is highly recommended to work with a physical therapist trained in hypermobility to modify these protocols, focusing on safe, isometric strength without overloading unstable joints.

Step 2: Pharmacological Sequencing (Medications)

If lifestyle adjustments aren’t enough, doctors will introduce medications. Because hEDS patients don’t all experience POTS in the exact same way, there is no single “correct” sequence of drugs [4][5]. Instead, doctors choose medications based on the underlying mechanisms driving your specific symptoms:

  • Volume Expanders (Fludrocortisone): This medication helps your kidneys retain sodium and water, effectively boosting your total blood volume [12][5]. Safety note: This drug can cause potassium depletion (hypokalemia), so your doctor will likely need to monitor your blood work and you may require a potassium supplement.
  • Vasoconstrictors (Midodrine): Midodrine causes your blood vessels to tighten (constrict), limiting the amount of blood that pools in your legs and abdomen when you stand up [12][5]. Safety note: Midodrine can cause dangerously high blood pressure when you are lying flat (supine hypertension). Patients are typically instructed not to take it within 3 to 4 hours of bedtime or before lying down to rest.
  • Heart Rate Modulators (Beta-blockers): These drugs block adrenaline, directly slowing down your racing heart [12][5]. However, they can sometimes cause significant fatigue, and they may be contraindicated for patients with severe asthma—a relevant concern given the high overlap of allergic-type conditions in this population [18][19].
  • Alternative Heart Rate Controllers (Ivabradine): If beta-blockers cause too much fatigue, drop your blood pressure too low, or worsen asthma, ivabradine is often the preferred next step [20][18]. It specifically slows the heart rate without affecting your blood pressure, and is frequently better tolerated [21][19].
  • Parasympathetic Enhancers (Pyridostigmine): Also known as Mestinon, this drug enhances nerve signals to improve blood vessel constriction and reduce heart rate spikes [22][23]. Safety note: Common side effects include severe gastrointestinal cramping and diarrhea (symptoms of cholinergic excess), which is especially important to monitor if you already have hEDS-related GI issues [24][25][26].

Treatment Challenges Unique to hEDS

Treating POTS in an hEDS patient is rarely straightforward because of overlapping conditions, often referred to as the “trifecta” (hEDS, POTS, and MCAS) [27][1][28].

  • Mast Cell Activation Syndrome (MCAS): If you have MCAS, your immune system may overreact to the inactive ingredients, dyes, or fillers (excipients) in your POTS medications [29][30]. Doctors and compounding pharmacies may need to work closely with you to find “clean” formulations of medications that don’t trigger severe allergic-type reactions [31][29]. Sometimes, addressing the mast cell issues directly can even improve dysautonomia symptoms [32][33].
  • Gastrointestinal Dysmotility: Stomach and bowel issues are highly prevalent in hEDS [34][7]. Delayed stomach emptying or chronic nausea can make it incredibly difficult to swallow large salt pills or massive amounts of water. Practical workarounds include sipping specialized oral rehydration solutions continuously rather than taking concentrated salt tablets. In severe cases where oral intake is impossible, doctors may temporarily prescribe IV saline infusions as a medical bridge to maintain blood volume [1][35].

Frequently Asked Questions

How do you treat POTS when you have hEDS?
Treatment typically starts with foundational lifestyle changes like increasing salt and fluid intake, wearing abdominal binders, and starting a modified exercise program. If these aren't enough, doctors can prescribe targeted medications based on your specific heart rate and blood pressure numbers.
Why are abdominal binders sometimes better than leg compression for hEDS patients?
Abdominal binders effectively prevent blood pooling in the stomach area without requiring you to pull tight stockings up your legs. This is particularly helpful for hEDS patients, as struggling with tight leg compression can sometimes cause hypermobile finger or wrist joints to dislocate.
What if I can't tolerate POTS medications because of my MCAS?
If Mast Cell Activation Syndrome (MCAS) causes you to react to inactive ingredients or dyes in your pills, your doctor can work with a compounding pharmacy. They can create clean formulations of your POTS medications without the specific fillers that trigger your allergic-type reactions.
What is the best way to exercise for POTS if my joints are hypermobile?
Graded exercise programs like the modified CHOP or Levine protocol are highly recommended for POTS. These start with seated or lying-down exercises like swimming or rowing, and should ideally be guided by a hypermobility-aware physical therapist to build strength without overloading unstable joints.
How can I get enough salt for my POTS if I have severe hEDS stomach issues?
Gastrointestinal issues like delayed stomach emptying can make it incredibly difficult to swallow large salt pills or massive amounts of water. Practical workarounds include sipping specialized oral rehydration solutions continuously throughout the day rather than taking concentrated salt tablets.

Questions for Your Doctor

  • • Which specific POTS medication class (blood volume expander, vasoconstrictor, or heart rate modulator) makes the most sense to try first based on my specific heart rate and blood pressure numbers?
  • • If I struggle to tolerate high salt and fluid intake due to GI issues, what alternative hydration workarounds or rehydration solutions do you recommend?
  • • Do I have symptoms of Mast Cell Activation Syndrome that warrant checking my POTS medications for specific triggers, fillers, or dyes?
  • • If beta-blockers make my baseline fatigue worse or trigger my asthma, am I a candidate for ivabradine?
  • • How frequently will my potassium levels need to be checked if I start taking a volume expander like fludrocortisone?
  • • Can you refer me to a physical therapist who specifically understands hypermobility to guide me through a modified POTS exercise protocol?

Questions for You

  • • Which lifestyle changes (salt, fluids, compression) have I successfully implemented, and which ones are currently too difficult to maintain due to GI pain or joint subluxations?
  • • When I stand up, do I primarily feel a racing, pounding heart, or do I feel dizzy, lightheaded, and notice my legs turning purple from blood pooling?
  • • How is my digestion reacting to my current salt and fluid intake, and do I need to switch from pills to liquids?
  • • Have I noticed any rash, flushing, or unusual allergic-type reactions when I start a new medication or supplement?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.

    Aziz Q, Harris LA, Goodman BP, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025; (23(8)):1291-1302 doi:10.1016/j.cgh.2025.02.015.

    PMID: 40387691
  2. 2

    Postural orthostatic tachycardia syndrome for the otolaryngologist.

    Bogle JM, Goodman BP, Barrs DM

    The Laryngoscope 2017; (127(5)):1195-1198 doi:10.1002/lary.26269.

    PMID: 27578452
  3. 3

    Recognizing postural orthostatic tachycardia syndrome.

    Pavlik D, Agnew D, Stiles L, Ditoro R

    JAAPA : official journal of the American Academy of Physician Assistants 2016; (29(4)):17-23 doi:10.1097/01.JAA.0000481398.76099.09.

    PMID: 26967958
  4. 4

    Treatment of Postural Orthostatic Tachycardia Syndrome With Medication: A Systematic Review.

    Hasan B, Almasri J, Marwa B, et al.

    Journal of child neurology 2020; (35(14)):1004-1016 doi:10.1177/0883073820948679.

    PMID: 32838632
  5. 5

    Predicting Therapeutic Efficacy of Pharmacological Treatments in Children with Postural Orthostatic Tachycardia Syndrome: A Mini-Review.

    Fan S, Cui Y, Liao Y, Jin H

    Children (Basel, Switzerland) 2023; (10(7)) doi:10.3390/children10071093.

    PMID: 37508589
  6. 6

    Therapy for fatigue and cognitive dysfunction in postural orthostatic tachycardia syndrome.

    Boris JR, Bernadzikowski T

    Cardiology in the young 2018; (28(12)):1415-1420 doi:10.1017/S1047951118001415.

    PMID: 30198448
  7. 7

    Prevalence and Predictors of Gastrointestinal Dysmotility in Patients with Hypermobile Ehlers-Danlos Syndrome: A Tertiary Care Center Experience.

    Alomari M, Hitawala A, Chadalavada P, et al.

    Cureus 2020; (12(4)):e7881 doi:10.7759/cureus.7881.

    PMID: 32489735
  8. 8

    Exercise Interventions in the Management of Postural Orthostatic Tachycardia Syndrome: A Scoping Review.

    Gonçalves Leite Rocco P, Reategui-Rivera CM, Finkelstein J

    Journal of multidisciplinary healthcare 2024; (17()):5867-5885 doi:10.2147/JMDH.S495088.

    PMID: 39678714
  9. 9

    The international POTS registry: Evaluating the efficacy of an exercise training intervention in a community setting.

    George SA, Bivens TB, Howden EJ, et al.

    Heart rhythm 2016; (13(4)):943-50.

    PMID: 26690066
  10. 10

    Effect of High Dietary Sodium Intake in Patients With Postural Tachycardia Syndrome.

    Garland EM, Gamboa A, Nwazue VC, et al.

    Journal of the American College of Cardiology 2021; (77(17)):2174-2184 doi:10.1016/j.jacc.2021.03.005.

    PMID: 33926653
  11. 11

    Pathophysiological mechanisms of Postural Orthostatic Tachycardia Syndrome analyzed by means of hemodynamics.

    Wei L, Cheng H, Chen S, et al.

    PloS one 2025; (20(7)):e0327236 doi:10.1371/journal.pone.0327236.

    PMID: 40601666
  12. 12

    Dysautonomia in the Ehlers-Danlos syndromes and hypermobility spectrum disorders-With a focus on the postural tachycardia syndrome.

    Mathias CJ, Owens A, Iodice V, Hakim A

    American journal of medical genetics. Part C, Seminars in medical genetics 2021; (187(4)):510-519 doi:10.1002/ajmg.c.31951.

    PMID: 34766441
  13. 13

    Prevalence of joint hypermobility syndromes in pediatric postural orthostatic tachycardia syndrome.

    Boris JR, Bernadzikowski T

    Autonomic neuroscience : basic & clinical 2021; (231()):102770 doi:10.1016/j.autneu.2020.102770.

    PMID: 33388686
  14. 14

    Abdominal-only Compression Garments Reduce Orthostatic Tachycardia and Improve Symptoms in Patients With Postural Orthostatic Tachycardia Syndrome.

    Bourne KM, Karalasingham K, Siddiqui T, et al.

    The Canadian journal of cardiology 2025; doi:10.1016/j.cjca.2025.11.038.

    PMID: 41338488
  15. 15

    A Portable, Active Abdominal Compression Binder for Orthostatic Intolerance: Design and Evaluation in Healthy Subjects.

    Emani VS, Escher A, Juraschek SP, Roche ET

    Annals of biomedical engineering 2026; doi:10.1007/s10439-025-03941-6.

    PMID: 41483109
  16. 16

    Assessing symptom improvement in patients with postural orthostatic tachycardia syndrome (POTS) following a 16-week structured exercise programme: a protocol for a randomised cross-over trial in a clinical outpatient setting.

    Kharraziha I, Zulj R, Holm H, et al.

    BMJ open 2025; (15(6)):e097057 doi:10.1136/bmjopen-2024-097057.

    PMID: 40588382
  17. 17

    Exercise rehabilitation for people with postural tachycardia syndrome at two secondary care centres in the UK: the PULSE feasibility randomised controlled trial.

    McGregor G, Evans B, Sandhu HK, et al.

    BMJ open 2025; (15(2)):e090197 doi:10.1136/bmjopen-2024-090197.

    PMID: 39987007
  18. 18

    Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications.

    Sathyamurthy I, Newale S

    Indian heart journal 2018; (70 Suppl 3()):S435-S441 doi:10.1016/j.ihj.2018.08.008.

    PMID: 30595304
  19. 19

    Ivabradine versus bisoprolol in the treatment of inappropriate sinus tachycardia: a long-term follow-up study.

    Martino A, Rebecchi M, Sette A, et al.

    Journal of cardiovascular medicine (Hagerstown, Md.) 2021; (22(11)):892-900 doi:10.2459/JCM.0000000000001203.

    PMID: 34747925
  20. 20

    Ivabradine in children with postural orthostatic tachycardia syndrome: a retrospective study.

    Towheed A, Nesheiwat Z, Mangi MA, et al.

    Cardiology in the young 2020; (30(7)):975-979 doi:10.1017/S1047951120001341.

    PMID: 32498748
  21. 21

    Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience.

    Ruzieh M, Sirianni N, Ammari Z, et al.

    Pacing and clinical electrophysiology : PACE 2017; (40(11)):1242-1245 doi:10.1111/pace.13182.

    PMID: 28846151
  22. 22

    The evidence for treatments for postural orthostatic tachycardia syndrome: a systematic review of randomized trials.

    Kwok CS, Lee S, Hall M, et al.

    Trends in cardiovascular medicine 2025; (35(8)):517-527 doi:10.1016/j.tcm.2025.07.001.

    PMID: 40653179
  23. 23

    Pyridostigmine improves hand grip strength in patients with myalgic encephalomyelitis/chronic fatigue syndrome.

    Schlömer E, Stein E, Kedor C, et al.

    Frontiers in neuroscience 2025; (19()):1637838 doi:10.3389/fnins.2025.1637838.

    PMID: 40970182
  24. 24

    Pharmacodynamics, Safety, and Tolerability of Pyridostigmine Bromide in Heart Failure.

    Goldberg R, Norcliffe-Kaufmann L, Kaufmann H, et al.

    Current therapeutic research, clinical and experimental 2025; (103()):100814 doi:10.1016/j.curtheres.2025.100814.

    PMID: 41357360
  25. 25

    Efficacy of pyridostigmine (Mestinon) in the relief of patients with epiphora.

    Yazicioglu T, Oklar M, İnan R

    Photodiagnosis and photodynamic therapy 2023; (41()):103240 doi:10.1016/j.pdpdt.2022.103240.

    PMID: 36592783
  26. 26

    Leukocytoclastic Vasculitis Secondary to Pyridostigmine (Mestinon): Report of a Possible First Case.

    Singh G, Hodgson T, Clarke DE

    The Permanente journal 2017; (21()):15-240 doi:10.7812/TPP/15-240.

    PMID: 28080955
  27. 27

    The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome.

    Wang E, Ganti T, Vaou E, Hohler A

    Allergy and asthma proceedings 2021; (42(3)):243-246 doi:10.2500/aap.2021.42.210022.

    PMID: 33980338
  28. 28

    Complex Presentations, Identification and Treatment of Mast Cell Activation Syndrome and Associated Conditions: A Case Report.

    Quinn AM

    Integrative medicine (Encinitas, Calif.) 2023; (22(4)):36-41.

    PMID: 37752934
  29. 29

    Recognition and Management of Medication Excipient Reactivity in Patients With Mast Cell Activation Syndrome.

    Schofield JR, Afrin LB

    The American journal of the medical sciences 2019; (357(6)):507-511 doi:10.1016/j.amjms.2019.03.005.

    PMID: 31126513
  30. 30

    Removal of Polymer Clips From the Gallbladder Fossa in a Patient With Ehlers-Danlos Syndrome (EDS) to Treat Mast Cell Activation Syndrome (MCAS): A Case Report.

    Xiao Y, Calixte DA, Fry E, Tiesenga F

    Cureus 2023; (15(1)):e33704 doi:10.7759/cureus.33704.

    PMID: 36788923
  31. 31

    Drug desensitization in 17-year-old male with Mast Cell Activation Syndrome, pneumonia, and antibiotic hypersensitivities.

    Staso P, Leonov A

    AME case reports 2017; (1()):7 doi:10.21037/acr.2017.11.03.

    PMID: 30263994
  32. 32

    Postural Tachycardia Syndrome in Children and Adolescents: Pathophysiology and Clinical Management.

    Chen G, Du J, Jin H, Huang Y

    Frontiers in pediatrics 2020; (8()):474 doi:10.3389/fped.2020.00474.

    PMID: 32974246
  33. 33

    Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome.

    Weinstock LB, Afrin LB, Reiersen AM, et al.

    Brain, behavior, & immunity - health 2025; (48()):101048 doi:10.1016/j.bbih.2025.101048.

    PMID: 40686928
  34. 34

    Mechanisms underlying reflux symptoms and dysphagia in patients with joint hypermobility syndrome, with and without postural tachycardia syndrome.

    Fikree A, Aziz Q, Sifrim D

    Neurogastroenterology and motility 2017; (29(6)) doi:10.1111/nmo.13029.

    PMID: 28191707
  35. 35

    Self-reported Demographics of 154 Hypermobile Ehlers-Danlos Syndrome Patients.

    Ploeg AN, Courseault J, Cheng WS

    American journal of physical medicine & rehabilitation 2025; (104(10)):927-932 doi:10.1097/PHM.0000000000002766.

    PMID: 40300043

This page provides educational information on POTS treatment strategies for hEDS patients. Always consult your cardiologist or autonomic specialist before starting medications, increasing salt intake, or beginning a new exercise routine.

Stay up to date

Get notified when new research about Hypermobile Ehlers-Danlos Syndrome (hEDS) is published.

No spam. Unsubscribe anytime.